Vickers Venture Fund VI Pte Ltd
CIK: 0001839162
Associated companies
Transaction History
| AARD | ▼ Sell | Other | 413,491 | — | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 1,637,411 | — | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 413,491 | — | 2/14/2025 | View on chart |
| AARD | ▼ Sell | Other | 1,637,411 | — | 2/14/2025 | View on chart |
We use analytics to understand how market-wall is used. No personal data is sold.
AI Market Commentary
AI-generatedAll commentary →Synthesized from recent news and fundamentals/technical data -- not human analyst commentary or trader sentiment.
September 28, 2026
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD)
RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.
RBC Capital Maintains Sector Perform Rating for Aardvark Therapeutics (AARD). RBC Capital has reiterated a Sector Perform rating for Aardvark Therapeutics and kept its $6 price target unchanged. The update comes amid a broader view that the company remains a solid play within its therapeutic area. Analysts’ average target is $11.11, suggesting a potential upside if the stock moves toward its 52‑week high. The rating signals continued confidence in the company’s prospects without a change in the valuation outlook.